As SOST is expressed by some prostate cancer cells, circulating sclerostin levels are usually significantly increased in prostate cancer patients and particularly in those receiving ADT,48 as androgens are key regulators of bone metabolism in this population. The gene discussed is SOST; the disease is prostate carcinoma.